AUTONOMIX MEDICAL INC
AMIXNASDAQTrading Snapshot
- Day Range
- $2.11 – $2.16
- 52-Week Range
- $2.05 – $32.55
- Volume (shares)
- 29,081
- Avg Volume (shares)
- —
- Shares Outstanding
- 2.0M
- Next Earnings
- 2026-11-11
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-46.50
- Dividend Yield
- —
- Dilution (1yr)
- +27.5%
AUTONOMIX MEDICAL INC
AMIX
StockOtter · stockotter.spaceAbout AUTONOMIX MEDICAL INC
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company’s technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Autonomix Medical Strengthens Patent Protection for Platform Technology Enabling Precision Access, Treatment Delivery and Procedural Validation
Patent expands protection for catheter-based technologies enabling transvascular access, treatment guidance, adaptive treatment delivery, and real-time procedural validation beyond the lumen wall
Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance
FDA pre-submission feedback supports a Class II strategy, leveraging substantial equivalence to a previously cleared device, positioning the Company for potential initial U.S. clearance of its standalone sensing platform
Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform
European patent strengthens protection for proprietary autonomic nervous system assessment technologies, further expanding Company's international patent portfolio
Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors
Appointment adds more than four decades of MedTech leadership, FDA regulatory and strategic transaction experience, including work supporting renal denervation and other category-defining technologies
Autonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026
Abstracts highlight potential of Autonomix's transvascular technology across pain management and nervous system mapping THE WOODLANDS, TX, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Auton
Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery
New patent broadens protection around systems integrating real-time physiological feedback, sensing and imaging with controlled therapeutic delivery, including neural ablation approaches for cancer pain